Anika Therapeutics (ANIK) Research & Development (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, Research & Development rose 10.79% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $26.4 million, a 4.88% increase from a year earlier, with the FY2025 full-year figure at $25.8 million, up 0.88% from the prior year.
• Research & Development for Q1 2026 stood at $6.7 million, up from $6.5 million in the prior quarter.
• Over the last five years, Research & Development for ANIK reached as high as $8.9 million in Q2 2023 and fell as low as -$3.3 million in Q4 2023.
• Historically, Research & Development has averaged $5.8 million across 5 years, with a median of $6.5 million in 2024.
• Across the five-year window, Research & Development sank 135.2% in 2022 and jumped 294.7% in 2024, its largest moves.
• Year by year, Research & Development stood at -$2.1 million in 2022, then tumbled by 58.24% to -$3.3 million in 2023, then soared by 294.7% to $6.5 million in 2024, then retreated by 0.85% to $6.5 million in 2025, then climbed by 4.05% to $6.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $6.7 million in Q1 2026, $6.5 million in Q4 2025, and $6.9 million in Q3 2025.